Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Journal of Medicinal Chemistry
|
February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series
Longbin Liu, Mark H Norman, Matthew Lee, et al.
Molecular Cancer Therapeutics
|
May 20, 2016
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E Hughes, Karen Rex, Sean Caenepeel, et al.
Journal of Medicinal Chemistry
|
June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J Giffin, Keegan Cooke, Edward K Lobenhofer, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 23, 2016
Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors
Ryan P Wurz, Christine Sastri, Derin C D'Amico, et al.
Journal of Medicinal Chemistry
|
September 4, 2008
Design, synthesis, and biological evaluation of potent c-Met inhibitors
Noel D D'Angelo, Steven F Bellon, Shon K Booker, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors
Alessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Journal of Medicinal Chemistry
|
April 23, 2008
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase
Brian K Albrecht, Jean-Christophe Harmange, David Bauer, et al.
Journal of Medicinal Chemistry
|
March 18, 2025
From DNA-Encoded Library Screening to <b>AM-9747</b>: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
Ian Sarvary, Mikkel Vestergaard, Loris Moretti, et al.
Cancer Discovery
|
September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
Brian Belmontes, Katherine K Slemmons, Chun Su, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Journal of Medicinal Chemistry
|
February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series
Longbin Liu, Mark H Norman, Matthew Lee, et al.
Molecular Cancer Therapeutics
|
May 20, 2016
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E Hughes, Karen Rex, Sean Caenepeel, et al.
Journal of Medicinal Chemistry
|
June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J Giffin, Keegan Cooke, Edward K Lobenhofer, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 23, 2016
Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors
Ryan P Wurz, Christine Sastri, Derin C D'Amico, et al.
Journal of Medicinal Chemistry
|
September 4, 2008
Design, synthesis, and biological evaluation of potent c-Met inhibitors
Noel D D'Angelo, Steven F Bellon, Shon K Booker, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors
Alessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Journal of Medicinal Chemistry
|
April 23, 2008
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase
Brian K Albrecht, Jean-Christophe Harmange, David Bauer, et al.
Journal of Medicinal Chemistry
|
March 18, 2025
From DNA-Encoded Library Screening to <b>AM-9747</b>: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
Ian Sarvary, Mikkel Vestergaard, Loris Moretti, et al.
Cancer Discovery
|
September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
Brian Belmontes, Katherine K Slemmons, Chun Su, et al.
Page
of 11